Creative Planning Exact Sciences Corp Transaction History

Creative Planning

$101 Billion
Q3 2024

A detailed history of Creative Planning transactions in Exact Sciences Corp stock. As of the latest transaction made, Creative Planning holds 38,060 shares of EXAS stock, worth $2.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,060

Previous 33,154 14.8%

Holding current value

$2.19 Million

Previous $1.4 Million 85.07%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 11, 2024	BUY	$42.43 - $70.83 $208,161 - $347,491	4,906 Added 14.8%	38,060 $2.59 Million
Q2 2024 Aug 15, 2024	BUY	$41.33 - $74.26 $204,748 - $367,884	4,954 Added 17.57%	33,154 $1.4 Million
Q1 2024 May 10, 2024	BUY	$56.27 - $73.77 $347,804 - $455,972	6,181 Added 28.07%	28,200 $1.95 Million
Q4 2023 Feb 14, 2024	BUY	$59.06 - $75.72 $139,440 - $178,774	2,361 Added 12.01%	22,019 $1.63 Million
Q3 2023 Nov 16, 2023	SELL	$65.94 - $99.04 $89,084 - $133,803	-1,351 Reduced 6.43%	19,658 $1.34 Million
Q2 2023 Jul 21, 2023	BUY	$62.68 - $95.05 $674,812 - $1.02 Million	10,766 Added 105.11%	21,009 $1.97 Million
Q1 2023 May 15, 2023	SELL	$47.19 - $70.77 $45,113 - $67,656	-956 Reduced 8.54%	10,243 $694,000
Q4 2022 Feb 10, 2023	SELL	$30.35 - $53.15 $526,390 - $921,833	-17,344 Reduced 60.76%	11,199 $554,000
Q3 2022 Nov 03, 2022	BUY	$31.97 - $49.37 $180,182 - $278,249	5,636 Added 24.6%	28,543 $927,000
Q2 2022 Aug 15, 2022	SELL	$35.61 - $76.23 $201,196 - $430,699	-5,650 Reduced 19.78%	22,907 $902,000
Q1 2022 May 16, 2022	BUY	$57.56 - $82.54 $385,536 - $552,852	6,698 Added 30.64%	28,557 $2 Million
Q4 2021 Feb 11, 2022	BUY	$72.5 - $100.68 $48,720 - $67,656	672 Added 3.17%	21,859 $1.7 Million
Q3 2021 Nov 10, 2021	BUY	$90.24 - $124.05 $1.39 Million - $1.91 Million	15,426 Added 267.77%	21,187 $2.02 Million
Q2 2021 Aug 04, 2021	SELL	$93.66 - $139.27 $360,591 - $536,189	-3,850 Reduced 40.06%	5,761 $716,000
Q1 2021 Apr 30, 2021	SELL	$116.57 - $155.01 $1.03 Million - $1.37 Million	-8,818 Reduced 47.85%	9,611 $1.27 Million
Q4 2020 Jan 29, 2021	SELL	$99.61 - $142.12 $1.76 Million - $2.51 Million	-17,634 Reduced 48.9%	18,429 $2.44 Million
Q3 2020 Nov 05, 2020	SELL	$72.92 - $102.01 $626,747 - $876,775	-8,595 Reduced 19.25%	36,063 $3.68 Million
Q2 2020 Jul 23, 2020	SELL	$55.75 - $92.75 $767,621 - $1.28 Million	-13,769 Reduced 23.57%	44,658 $3.88 Million
Q1 2020 May 05, 2020	SELL	$37.9 - $104.44 $294,558 - $811,707	-7,772 Reduced 11.74%	58,427 $3.39 Million
Q4 2019 Jan 30, 2020	SELL	$77.66 - $99.74 $1.1 Million - $1.41 Million	-14,168 Reduced 17.63%	66,199 $6.12 Million
Q3 2019 Nov 01, 2019	BUY	$90.37 - $122.49 $1.81 Million - $2.45 Million	19,976 Added 33.08%	80,367 $7.26 Million
Q2 2019 Jul 26, 2019	SELL	$89.51 - $118.04 $1.11 Million - $1.47 Million	-12,422 Reduced 17.06%	60,391 $7.13 Million
Q1 2019 Apr 24, 2019	BUY	$61.98 - $96.5 $386,817 - $602,256	6,241 Added 9.37%	72,813 $6.31 Million
Q4 2018 Feb 01, 2019	BUY	$56.04 - $82.66 $541,626 - $798,908	9,665 Added 16.98%	66,572 $4.2 Million
Q3 2018 Oct 25, 2018	SELL	$48.29 - $80.6 $471,310 - $786,656	-9,760 Reduced 14.64%	56,907 $4.49 Million
Q2 2018 Jul 20, 2018	SELL	$37.84 - $69.96 $263,555 - $487,271	-6,965 Reduced 9.46%	66,667 $3.99 Million
Q1 2018 Apr 18, 2018	BUY	$39.82 - $57.53 $809,381 - $1.17 Million	20,326 Added 38.13%	73,632 $2.97 Million
Q4 2017 Jan 17, 2018	SELL	$46.49 - $60.51 $188,842 - $245,791	-4,062 Reduced 7.08%	53,306 $2.8 Million
Q3 2017 Oct 17, 2017	BUY	$37.05 - $47.12 $2.13 Million - $2.7 Million	57,368	57,368 $2.7 Million

Others Institutions Holding EXAS

# of Institutions

673

Shares Held

162M

Call Options Held

2.58M

Put Options Held

2.19M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Exact Sciences Corp Transaction History